Sousa, Alexander A.
Hemez, Colin
Lei, Lei
Traore, Soumba
Kulhankova, Katarina
Newby, Gregory A.
Doman, Jordan L.
Oye, Keyede
Pandey, Smriti
Karp, Philip H.
McCray, Paul B. Jr
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL152960, P01HL152960)
Howard Hughes Medical Institute (Liu investigatorship)
Article History
Received: 28 December 2023
Accepted: 12 June 2024
First Online: 10 July 2024
Competing interests
: A.A.S., C.H. and D.R.L. have filed patent applications on prime editing through the Broad Institute. P.B.M.J. is on the supervisory advisory board and performs sponsored research for Spirovant Sciences, Inc. D.R.L. is a consultant and equity owner of Prime Medicine, Beam Therapeutics, Pairwise Plants, Exo Therapeutics, Nvelop Therapeutics and Chroma Medicine, all companies that use or deliver genome editing or epigenome-modulating agents. The other authors declare no competing interests.